AVXL - coming catalysts and stock price

"In the same space, Anavex (AVXL) targets sigma-1 receptor with two candidates, 2-73 and 3-71. There is some impressive data for a sub-group of patients who has been on 2-73 for over four years without symptom deterioration. More importantly, 2-73 has been in a registration trial for AD for over two years and most likely is ahead of SAVA three years." 

"We project AVXL to be in the $40~45 range per share within a year with positive Rett result, partially positive result from Parkinson trial (positive only for those patients with certain genetic markers) and the completion of recruitment for AD trial."

[Reference] 

1. https://www.biotechtoinvest.com/research/2020/9/15/all-roads-lead-to-rome-compounds-from-avxl-and-sava-likely-target-the-same-sets-of-molecules

2. https://seekingalpha.com/article/4415664-anavex-and-cassava-sciences-closer-to-understanding-alzheimers-disease